C.R. Sincock

C.R. Sincock has a diverse portfolio of work experience. They began their career as a Summer Intern at Acuity Brands in 2006. In 2007, they worked as an Investment Analyst at QVT Financial LP. From 2008 to 2018, Sincock held various roles at Avfuel Corporation, including Managing Director of Business Development and Director of International Business Development. In 2014, they founded Transhuman Capital and served as the Managing Partner. Sincock joined Avflight Corporation as CEO in 2017 and became an Executive Vice President at Avfuel Corporation in 2019. They also became a Founding Investor and Board Member at Kriya Therapeutics in 2019. In 2021, Sincock co-founded Dvant Pharma and served as the Executive Chairman. They also joined the National Air Transportation Association as a Board Member and the University of Michigan Biomedical Venture Fund as an Investment Advisory Board Member in 2021.

C.R. Sincock's education history begins in 2003 when they enrolled at Harvard University. They pursued a Bachelor of Arts degree in Economics and completed their studies in 2007. Afterward, in 2011, C.R. Sincock joined the prestigious Harvard Business School and obtained a Master of Business Administration (M.B.A.) degree by 2013, although the field of study is not specified. Lastly, C.R. Sincock is currently pursuing a Master of Science (M.S.) degree in Biotechnology at The Johns Hopkins University, which they began in 2021 and are expected to complete in 2025.